* patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to tocilizumab or dxm or to any of their excipients. * pregnancy * current documented bacterial infection not controlled by antibiotics. * certain evolving viral diseases (especially active herpes, chickenpox, shingles), * psychotic states still not controlled by treatment, * live vaccines in the previous 4 weeks, * active tuberculosis or disseminated strongyloidiasis * patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

* patients with exclusion criteria to the corimuno-19 cohort. * known hypersensitivity to tocilizumab or dxm or to any of their excipients. * pregnancy * current documented bacterial infection not controlled by antibiotics. * certain evolving viral diseases (especially active herpes, chickenpox, shingles), * psychotic states still not controlled by treatment, * live vaccines in the previous 4 weeks, * active tuberculosis or disseminated strongyloidiasis * patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: * absolute neutrophil count (anc) ≤ 1.0 x 109/l * haemoglobin level: no limitation * platelets (plt) \< 50 g /l * sgot or sgpt \> 5n

patients with exclusion criteria to the corimuno-19 cohort. known hypersensitivity to tocilizumab or dxm or to any of their excipients. pregnancy current documented bacterial infection not controlled by antibiotics. certain evolving viral diseases (especially active herpes, chickenpox, shingles), psychotic states still not controlled by treatment, live vaccines in the previous 4 weeks, active tuberculosis or disseminated strongyloidiasis patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: absolute neutrophil count (anc) ≤ 1.0 x 109/l haemoglobin level: no limitation platelets (plt) < 50 g /l sgot or sgpt > 5n

patients with exclusion criteria to the corimuno-19 cohort. known hypersensitivity to tocilizumab or dxm or to any of their excipients. pregnancy current documented bacterial infection not controlled by antibiotics. certain evolving viral diseases (especially active herpes, chickenpox, shingles), psychotic states still not controlled by treatment, live vaccines in the previous 4 weeks, active tuberculosis or disseminated strongyloidiasis patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: absolute neutrophil count (anc) ≤ 1.0 x 109/l haemoglobin level: no limitation platelets (plt) < 50 g /l sgot or sgpt > 5n

None

None

- patients with exclusion criteria to the corimuno-19 cohort. - known hypersensitivity to tocilizumab or dxm or to any of their excipients. - pregnancy - current documented bacterial infection not controlled by antibiotics. - certain evolving viral diseases (especially active herpes, chickenpox, shingles), - psychotic states still not controlled by treatment, - live vaccines in the previous 4 weeks, - active tuberculosis or disseminated strongyloidiasis - patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n

- patients with exclusion criteria to the corimuno-19 cohort. - known hypersensitivity to tocilizumab or dxm or to any of their excipients. - pregnancy - current documented bacterial infection not controlled by antibiotics. - certain evolving viral diseases (especially active herpes, chickenpox, shingles), - psychotic states still not controlled by treatment, - live vaccines in the previous 4 weeks, - active tuberculosis or disseminated strongyloidiasis - patient with any of following laboratory results out of the ranges detailed below at screening should be discussed depending of the medication: - absolute neutrophil count (anc) ≤ 1.0 x 109/l - haemoglobin level: no limitation - platelets (plt) < 50 g /l - sgot or sgpt > 5n